Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track

Aug 11, 2025

ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.12% during intraday trading on Monday, following an announcement regarding the adoption of its bladder cancer treatment, Anktiva®, by a prominent VA hospital.

The company revealed that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients. This development marks a significant milestone for ImmunityBio, as it represents the expansion of Anktiva®'s availability within the Veterans Affairs healthcare system.

Investors appear to be reacting positively to this news, likely seeing it as a sign of growing acceptance and potential increased demand for ImmunityBio's flagship product. The administration of Anktiva® in VA hospitals could lead to wider adoption across the VA healthcare system, potentially boosting the company's revenue and market presence in the oncology field. As ImmunityBio continues to expand the reach of Anktiva®, the market will be watching closely for signs of further uptake and success in treating bladder cancer patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152478805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152478805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152478805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152478805","market":"nz","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer","media":"Stock Track","content":"<p>ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.12% during intraday trading on Monday, following an announcement regarding the adoption of its bladder cancer treatment, Anktiva®, by a prominent VA hospital.</p>\n\n<p>The company revealed that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients. This development marks a significant milestone for ImmunityBio, as it represents the expansion of Anktiva®'s availability within the Veterans Affairs healthcare system.</p>\n\n<p>Investors appear to be reacting positively to this news, likely seeing it as a sign of growing acceptance and potential increased demand for ImmunityBio's flagship product. The administration of Anktiva® in VA hospitals could lead to wider adoption across the VA healthcare system, potentially boosting the company's revenue and market presence in the oncology field. As ImmunityBio continues to expand the reach of Anktiva®, the market will be watching closely for signs of further uptake and success in treating bladder cancer patients.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-11 22:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.12% during intraday trading on Monday, following an announcement regarding the adoption of its bladder cancer treatment, Anktiva®, by a prominent VA hospital.</p>\n\n<p>The company revealed that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients. This development marks a significant milestone for ImmunityBio, as it represents the expansion of Anktiva®'s availability within the Veterans Affairs healthcare system.</p>\n\n<p>Investors appear to be reacting positively to this news, likely seeing it as a sign of growing acceptance and potential increased demand for ImmunityBio's flagship product. The administration of Anktiva® in VA hospitals could lead to wider adoption across the VA healthcare system, potentially boosting the company's revenue and market presence in the oncology field. As ImmunityBio continues to expand the reach of Anktiva®, the market will be watching closely for signs of further uptake and success in treating bladder cancer patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1152478805","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152478805","pubTimestamp":1754921554,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.12% during intraday trading on Monday, following an announcement regarding the adoption of its bladder cancer treatment, Anktiva®, by a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|随着VA医院开始给药Anktiva，ImmunityBio飙升5.12%®用于膀胱癌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (IBRX) saw its stock price soar by 5.12% during intraday trading on Monday, following an announcement regarding the adoption of its bladder cancer treatment, Anktiva®, by a prominent VA hospital.\nThe company revealed that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients. This development marks a significant milestone for ImmunityBio, as it represents the expansion of Anktiva®'s availability within the Veterans Affairs healthcare system.\nInvestors appear to be reacting positively to this news, likely seeing it as a sign of growing acceptance and potential increased demand for ImmunityBio's flagship product. The administration of Anktiva® in VA hospitals could lead to wider adoption across the VA healthcare system, potentially boosting the company's revenue and market presence in the oncology field. As ImmunityBio continues to expand the reach of Anktiva®, the market will be watching closely for signs of further uptake and success in treating bladder cancer patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}